18.227.81.186
dgid:
enl:
npi:0
Home Once-weekly GHD treatment shows potential in phase 3 trial

Growth Hormone Deficiency

Once-weekly GHD treatment shows potential in phase 3 trial

  Once-weekly somapacitan (Sogroya; Novo Nordisk) injection in children with growth hormone deficiency (GHD) appears to be non-inferior to somatropin daily injection, according to data presented at the Endocrine Society’s Annual Meeting 2022. In the phase 3 REAL 4 study, 200 children with GH treatment naïve GHD were randomly assigned...

Read More
By rd360stg
Long-term study deems weekly long-acting GH safe, effective in children with GHD
By rd360stg
Long-term data support use of growth hormone in adults with GHD
By rd360stg
How has the pandemic impacted pediatric endocrinology?
By rd360stg
No link between GH replacement and primary tumor or cancer recurrence
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
Outcomes ‘as expected’ with weekly lonapegsomatropin in children with GHD
By rd360stg
Is long-acting rhGH formulations viable in GH deficiency treatment?
By rd360stg
Adult GHD may improve after transsphenoidal surgery in young adults
By rd360stg
Isolated GH deficiency reduces dental arch growth
-Advertisement-
-Advertisement-
-Advertisement=-
By rd360stg
Do short periods of poor adherence with rhGH impact height?
By rd360stg
Understanding the cardiometabolic risk profile in growth hormone deficiency
By rd360stg
Did pandemic-associated lockdowns increase adherence to therapy for GHD?
By rd360stg
FDA denies approval of somatrogon for growth hormone deficiency
-Advertisement-
-Advertisement-
-Advertisement-

Contact

Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809

+908-505-8899
[email protected]

Social Links

© 2024 Med Journal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved
-Advertisement-
-Advertisement-